Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide for post renal transplant anemia
ChiCTR2500103364Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2025
- Modality
- PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peglmolesatide in anaemia and anemia of renal disease, sponsored by West China Hospital of Sichuan University. Primary endpoint: Mean change in hemoglobin at week 12 from baseline. Planned start May 2025; status: not yet recruiting.
02
Drugs
peglmolesatide
03
Conditions
anaemiaanemia of renal disease
Beyond the preview
Go deeper on ChiCTR2500103364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103364.